Tirzepatide Superior to Intensified Conventional Care in Early Type 2 Diabetes: Trial Reveals
USA: In a recent randomized controlled trial, Tirzepatide demonstrated significantly greater improvements than intensified conventional care (ICC) in adults with early type 2 diabetes inadequately controlled on metformin. Tirzepatide led to larger reductions in HbA1c, body weight, waist circumference, and BMI.
Additionally, a markedly higher proportion of participants receiving tirzepatide achieved normoglycemia (HbA1c <5.7%) compared with those receiving ICC, highlighting its strong potential for early intensive diabetes management.
The findings, published in Annals of Internal Medicine, are from the SURPASS-EARLY phase 4 trial, a multicenter, open-label study conducted across 78 sites in 10 countries. Led by Stefano Del Prato from the Interdisciplinary Research Center for Health Science, Sant’Anna School of Advanced Studies, Pisa, Italy, and colleagues, the study evaluated whether early initiation of tirzepatide could deliver superior long-term metabolic outcomes compared with guideline-based intensified standard therapy.
A total of 794 adults with type 2 diabetes of up to four years’ duration, all of whom were on metformin but had inadequate glycemic control, were enrolled. Participants were randomized to receive either once-weekly tirzepatide (up to 15 mg or maximum tolerated dose) or intensified conventional care, which included standard glucose-lowering therapies such as GLP-1 receptor agonists excluding tirzepatide, selected according to clinical practice and local guidelines.
The primary objective of the trial was to establish whether tirzepatide was at least non-inferior to ICC in reducing HbA1c levels over two years. Secondary endpoints focused on superiority outcomes, including changes in glycemic control, body weight, and waist circumference.
The researchers reported the following findings:
- After 2 years, tirzepatide met non-inferiority criteria and showed clear superiority over intensified conventional care (ICC) across key metabolic outcomes.
- HbA1c reduction was greater with tirzepatide compared with ICC (−1.99 vs −1.32 percentage points), with a significant treatment difference of −0.68 percentage points.
- Weight loss was more pronounced in the tirzepatide group, with an estimated treatment difference of −8.0 kg versus ICC.
- Waist circumference reduction also favored tirzepatide, with a difference of −6.2 cm compared with conventional care.
- Nearly 60.2% of participants receiving tirzepatide achieved normoglycemia (HbA1c <5.7%), compared with 24.0% in the ICC group.
- Gastrointestinal adverse events were the most commonly reported side effects in both treatment groups, consistent with incretin-based therapies.
The study was open-label, which the authors acknowledge as a key limitation, although the large sample size and long follow-up strengthen the robustness of the findings.
Overall, the trial suggests that early use of tirzepatide in type 2 diabetes may offer substantial advantages over conventional stepwise intensification strategies, achieving greater and more sustained improvements in glycemic control and body weight over two years.
Reference:
Del Prato S, Heine RJ, Pérez Manghi FC, Hsia SH, Gomez-Valderas E, Zeytinoglu M, Razzoli E, Kiljanski J, Sharma P, Knights A, Thieu VT. Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes: A Randomized Clinical Trial. Ann Intern Med. 2026 May 26. doi: 10.7326/ANNALS-25-05602. Epub ahead of print. PMID: 42184419.
Next Story